Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
1.
J Infect Dis ; 225(8): 1460-1470, 2022 04 19.
Artículo en Inglés | MEDLINE | ID: mdl-33895843

RESUMEN

Vaccines against Staphylococcus aureus have eluded researchers for >3 decades while the burden of staphylococcal diseases has increased. Early vaccine attempts mainly used rodents to characterize preclinical efficacy, and all subsequently failed in human clinical efficacy trials. More recently, leukocidin AB (LukAB) has gained interest as a vaccine antigen. We developed a minipig deep surgical wound infection model offering 3 independent efficacy readouts: bacterial load at the superficial and at the deep-seated surgical site, and dissemination of bacteria. Due to similarities with humans, minipigs are an attractive option to study novel vaccine candidates. With this model, we characterized the efficacy of a LukAB toxoid as vaccine candidate. Compared to control animals, a 3-log reduction of bacteria at the deep-seated surgical site was observed in LukAB-treated minipigs and dissemination of bacteria was dramatically reduced. Therefore, LukAB toxoids may be a useful addition to S. aureus vaccines and warrant further study.


Asunto(s)
Infecciones Estafilocócicas , Vacunas Estafilocócicas , Animales , Carga Bacteriana , Proteínas Bacterianas , Leucocidinas , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus , Infección de la Herida Quirúrgica/prevención & control , Porcinos , Porcinos Enanos , Vacunación
2.
Clin Infect Dis ; 72(7): 1211-1219, 2021 04 08.
Artículo en Inglés | MEDLINE | ID: mdl-32406495

RESUMEN

BACKGROUND: Escherichia coli is the most common cause of bacteremia in high-income countries. To enable the development and implementation of effective prevention strategies, a better understanding of the current epidemiology of invasive E. coli infections is needed. METHODS: A systematic review of literature published between 1 January 2007 and 31 March 2018 on the burden and epidemiology of E. coli bacteremia in populations that include adults in high-income countries was conducted. Meta-analysis was performed for descriptive purposes. RESULTS: During the studied time interval, the estimated incidence rate of E. coli bacteremia was 48 per 100 000 person-years, but this increased considerably with age: rates per 100 000 person-years were >100 in 55-to-75-year-olds and >300 in 75-to-85-year-olds. Overall, E. coli accounted for 27% of documented bacteremia episodes: 18% if hospital acquired, 32% if community-onset healthcare associated, and 33% if community acquired. The estimated case fatality rate was 12%. Approximately 44% of episodes were community acquired, 27% community-onset healthcare associated, and 27% hospital acquired. Urinary tract infection (UTI) was the primary source for 53% of episodes. CONCLUSIONS: This systematic review confirms the substantial burden of E. coli bacteremia in older adults and justifies the implementation of community-level programs to prevent E. coli bacteremia and ideally UTI in this age group.


Asunto(s)
Bacteriemia , Infecciones Comunitarias Adquiridas , Infecciones por Escherichia coli , Infecciones Urinarias , Anciano , Bacteriemia/epidemiología , Infecciones Comunitarias Adquiridas/epidemiología , Escherichia coli , Infecciones por Escherichia coli/epidemiología , Humanos , Infecciones Urinarias/epidemiología
3.
Ned Tijdschr Geneeskd ; 1642020 09 01.
Artículo en Holandés | MEDLINE | ID: mdl-32940986

RESUMEN

Vaccines were originally developed to prevent potentially deadly childhood diseases, but during the 21st century attention broadened to include prevention of infection in all stages of life. Prevention and treatment of bacterial infections are two of the biggest public health challenges of the 21st century. A crisis threatens to arise as the ageing of the population and the associated increase in cases of life-threatening bacteraemia and healthcare-associated infection coincides with an increase in antimicrobial resistance.


Asunto(s)
Antibacterianos/inmunología , Infecciones Bacterianas/prevención & control , Vacunas Bacterianas/inmunología , Infección Hospitalaria/prevención & control , Descubrimiento de Drogas/tendencias , Adulto , Anciano , Anciano de 80 o más Años , Bacteriemia/inmunología , Bacteriemia/prevención & control , Bacterias/inmunología , Infecciones Bacterianas/inmunología , Niño , Infección Hospitalaria/inmunología , Historia del Siglo XXI , Humanos , Persona de Mediana Edad
4.
NPJ Vaccines ; 5: 84, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32963814

RESUMEN

A crisis in bacterial infections looms as ageing populations, increasing rates of bacteraemia and healthcare-associated infections converge with increasing antimicrobial resistance and a paucity of new antimicrobial classes. New initiatives are needed to develop bacterial vaccines for older adults in whom immune senescence plays a critical role. Novel vaccines require an expanded repertoire to prevent mucosal diseases such as pneumonia, skin and soft tissue infections and urinary tract infections that are major causes of morbidity and mortality in the elderly, and key drivers of antimicrobial resistance. This review considers the challenges inherent to the prevention of bacterial diseases, particularly mucosal infections caused by major priority bacterial pathogens against which current vaccines are sub-optimal. It has become clear that prevention of many lung, urinary tract and skin infections requires more than circulating antibodies. Induction of Th1/Th17 cellular responses with tissue-resident memory (Trm) cells homing to mucosal tissues may be a pre-requisite for success.

5.
Expert Rev Vaccines ; 17(7): 607-618, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29902092

RESUMEN

INTRODUCTION: Bacteremia and healthcare-associated infections (HAIs) continue to rise in industrialized countries, in line with population aging and increased healthcare needs. Escherichia coli and Staphylococcus aureus are the most common pathogens causing HAIs and bacteremia. AREAS COVERED: This review discusses risk factors in the healthcare setting contributing to the rise in bacteremia and other invasive bacterial HAIs in older populations in general, and attributed to E. coli and S. aureus. Treatment of infections is becoming increasingly difficult due to emerging antimicrobial resistance. Prophylactic vaccines may be the solution to lowering the burden of serious infections in the elderly. EXPERT COMMENTARY: E. coli and S. aureus vaccines routinely administered to older adults and to people undergoing prescheduled procedures with high infection risks could prevent a significant proportion of severe disease, and could potentially also limit the further emergence of antimicrobial resistance.


Asunto(s)
Bacteriemia/prevención & control , Infecciones por Escherichia coli/prevención & control , Infecciones Estafilocócicas/prevención & control , Anciano , Bacteriemia/microbiología , Infección Hospitalaria/inmunología , Infección Hospitalaria/microbiología , Infección Hospitalaria/prevención & control , Escherichia coli/inmunología , Infecciones por Escherichia coli/inmunología , Vacunas contra Escherichia coli/administración & dosificación , Vacunas contra Escherichia coli/inmunología , Humanos , Factores de Riesgo , Infecciones Estafilocócicas/inmunología , Vacunas Estafilocócicas/administración & dosificación , Vacunas Estafilocócicas/inmunología , Staphylococcus aureus/inmunología
6.
Clin Vaccine Immunol ; 24(12)2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28971965

RESUMEN

The global burden of disease caused by extraintestinal pathogenic Escherichia coli (ExPEC) is increasing as the prevalence of multidrug-resistant strains rises. A multivalent ExPEC O-antigen bioconjugate vaccine could have a substantial impact in preventing bacteremia and urinary tract infections. Development of an ExPEC vaccine requires a readout to assess the functionality of antibodies. We developed an opsonophagocytic killing assay (OPA) for four ExPEC serotypes (serotypes O1A, O2, O6A, and O25B) based on methods established for pneumococcal conjugate vaccines. The performance of the assay was assessed with human serum by computing the precision, linearity, trueness, total error, working range, and specificity. Serotypes O1A and O6A met the acceptance criteria for precision (coefficient of variation for repeatability and intermediate precision, ≤50%), linearity (90% confidence interval of the slope of each strain, 0.80, 1.25), trueness (relative bias range, -30% to 30%), and total error (total error range, -65% to 183%) at five serum concentrations and serotypes O2 and O25B met the acceptance criteria at four concentrations (the lowest concentration for serotypes O2 and O25B did not meet the system suitability test of maximum killing of ≥85% of E. coli cells). All serotypes met the acceptance criteria for specificity (opsonization index value reductions of ≤20% for heterologous serum preadsorption and ≥70% for homologous serum preadsorption). The assay working range was defined on the basis of the lowest and highest concentrations at which the assay jointly fulfilled the target acceptance criteria for linearity, precision, and accuracy. An OPA suitable for multiple E. coli serotypes has been developed, qualified, and used to assess the immunogenicity of a 4-valent E. coli bioconjugate vaccine (ExPEC4V) administered to humans.


Asunto(s)
Vacunas contra Escherichia coli/inmunología , Inmunoensayo/métodos , Proteínas Opsoninas/inmunología , Fagocitosis , Humanos , Sensibilidad y Especificidad
7.
Vaccine ; 34(35): 4152-4160, 2016 07 29.
Artículo en Inglés | MEDLINE | ID: mdl-27395567

RESUMEN

BACKGROUND: Extra-intestinal pathogenic Escherichia coli (ExPEC) are major human pathogens; however, no protective vaccine is currently available. We assessed in animal models the immunogenicity and safety of a 4-valent E. coli conjugate vaccine (ExPEC-4V, serotypes O1, O2, O6 and O25 conjugated to Exotoxin A from Pseudomonas aeruginosa (EPA)) produced using a novel in vivo bioconjugation method. METHODS: Three doses of ExPEC-4V (with or without aluminum hydroxide) were administered to rabbits (2µg or 20µg per O-antigen, subcutaneously), mice (0.2µg or 2µg per O-antigen, subcutaneously) and rats (0.4µg or 4µg per O-antigen, intramuscularly). Antibody persistence and boostability were evaluated in rats using O6-EPA monovalent conjugate (0.4µg O-antigen/dose, intramuscularly). Toxicity was assessed in rats (16µg total polysaccharide, intramuscularly). Serum IgG and IgM antibodies were measured by ELISA. RESULTS: Robust antigen-specific IgG responses were observed in all animal models, with increased responses in rabbits when administered with adjuvant. O antigen-specific antibody responses persisted up to 168days post-priming. Booster immunization induced a rapid recall response. Toxicity of ExPEC-4V when administered to rats was considered to be at the no observed adverse effect level. CONCLUSIONS: ExPEC-4V conjugate vaccine showed good immunogenicity and tolerability in animal models supporting progression to clinical evaluation.


Asunto(s)
Infecciones por Escherichia coli/prevención & control , Vacunas contra Escherichia coli/inmunología , Inmunogenicidad Vacunal , Antígenos O/inmunología , ADP Ribosa Transferasas/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Animales , Anticuerpos Antibacterianos/sangre , Toxinas Bacterianas/inmunología , Escherichia coli , Exotoxinas/inmunología , Femenino , Inmunización Secundaria , Ratones , Ratones Endogámicos ICR , Nivel sin Efectos Adversos Observados , Conejos , Ratas , Ratas Sprague-Dawley , Pruebas de Toxicidad , Vacunas Conjugadas/inmunología , Factores de Virulencia/inmunología , Exotoxina A de Pseudomonas aeruginosa
8.
Expert Rev Vaccines ; 15(1): 69-80, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26559122

RESUMEN

Support is growing for maternal immunization using acellular pertussis (aP) vaccines to prevent severe pertussis disease and deaths among very young, unvaccinated infants. Vaccine effectiveness of maternal immunization is 91% in preventing laboratory-confirmed pertussis in infants aged <3 months. To date, most mothers were primed in childhood with whole-cell pertussis vaccines. Soon, the generation of aP-primed individuals will become the new mothers-to-be. The shorter duration of protection afforded by aP vaccines, which is more pronounced with repeated aP boosters, may lead to increased pertussis circulation among aP-primed parents. Maternal Tdap immunization in aP-primed mothers-to-be may become less effective. Additional measures to protect young infants may eventually be needed, along with new vaccines that induce higher quality and more durable responses.


Asunto(s)
Transmisión de Enfermedad Infecciosa/prevención & control , Inmunización/métodos , Vacuna contra la Tos Ferina/administración & dosificación , Vacuna contra la Tos Ferina/inmunología , Tos Ferina/epidemiología , Tos Ferina/prevención & control , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Persona de Mediana Edad , Embarazo , Vacunas Acelulares/administración & dosificación , Vacunas Acelulares/inmunología , Adulto Joven
9.
J Infect Dis ; 213(1): 6-13, 2016 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-26333944

RESUMEN

Extraintestinal pathogenic Escherichia coli (ExPEC) is the most common gram-negative bacterial pathogen in humans. ExPEC causes the vast majority of urinary tract infections (UTIs), is a leading cause of adult bacteremia, and is the second most common cause of neonatal meningitis. Increasing multidrug resistance among ExPEC strains constitutes a major obstacle to treatment and is implicated in increasing numbers of hospitalizations and deaths and increasing healthcare costs associated with ExPEC infections. An effective vaccine against ExPEC infection is urgently needed. The O antigen, a component of the surface lipopolysaccharide, has been identified as a promising vaccine target. With the availability of a novel bioconjugation technology it is expected that multivalent O antigen conjugate vaccines can be produced at industrial scale. Clinical proof of concept of a 4-valent O antigen conjugate vaccine is ongoing. An ExPEC vaccine effective against strains that are associated with major diseases and resistant to multiple drugs could be routinely delivered to individuals at risk of developing severe E. coli infection, such as elderly people, individuals undergoing abdominal surgery and prostatic biopsy procedures, and persons at risk of recurrent and/or complicated UTI.


Asunto(s)
Infecciones por Escherichia coli , Vacunas contra Escherichia coli , Escherichia coli , Farmacorresistencia Bacteriana , Humanos , Antígenos O , Infecciones Urinarias
10.
Expert Rev Vaccines ; 14(9): 1277-87, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26204792

RESUMEN

Vaccines targeting Neisseria meningitidis serogroup B (MenB) have been attempted for 40 years. Monovalent outer membrane vesicle vaccines targeted at epidemic outbreaks have been successfully developed. Newer vaccines aim to induce antibodies to cross-reactive antigens, such as factor H binding protein (rLP2086) or a mix of outer membrane vesicle, factor H binding protein and other minor antigens (4CMenB). The true protective coverage among circulating MenB isolates afforded by these vaccines is unknown. Carefully conducted Phase IV post-implementation evaluations designed to measure specific effectiveness against major circulating MenB clonal lineages are needed to address the critical question of which antigens are linked to protection. Progress with whole-genome sequencing and bio-informatics may allow the composition of antigen mozaics based on two major outer membrane proteins: PorA and FetA.


Asunto(s)
Meningitis Meningocócica/prevención & control , Vacunas Meningococicas/inmunología , Neisseria meningitidis Serogrupo B/inmunología , Animales , Humanos , Meningitis Meningocócica/inmunología , Meningitis Meningocócica/microbiología , Vacunas Meningococicas/administración & dosificación , Resultado del Tratamiento
11.
Vaccine ; 33(4): 577-84, 2015 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-24176494

RESUMEN

BACKGROUND: The protection elicited by polysaccharide pneumococcal vaccines against community-acquired pneumonia in older adults remains debatable. Alternative vaccine targets include well-conserved pneumococcal protein antigens, such as pneumococcal histidine triad protein D (PhtD). OBJECTIVE: To evaluate humoral and cellular immune responses and safety/reactogenicity following immunisation with PhtD vaccine with or without adjuvant (alum or AS02V) in older (≥65 years) and young (18-45 years) healthy adults. METHODS: Two phase I/II, single-blind, parallel-group studies were conducted in 150 older and 147 young adults. Participants were randomised to receive 2 doses (months 0 and 2) of PhtD 30 µg, PhtD 10 µg plus alum, PhtD 30 µg plus alum, PhtD 10 µg plus AS02V or PhtD 30 µg plus AS02V, or the 23-valent polysaccharide pneumococcal vaccine (23PPV) at month 0 with placebo (saline solution) at month 2. Safety/reactogenicity was assessed. PhtD-specific antibody, T cell and memory B cell responses were evaluated. RESULTS: Solicited adverse events were more common in young participants and with adjuvanted vaccines. No vaccine-related serious adverse events were reported. Although anti-PhtD geometric mean antibody concentrations (GMCs) were consistently lower in the older adult cohort than in young adults, GMCs in the older cohort following PhtD 30 µg plus AS02V were comparable to those induced by plain PhtD or PhtD 30 µg plus alum in the young cohort. Compared with alum adjuvant, AS02V adjuvant system was associated with an increased frequency of PhtD-specific CD4 cells in both cohorts and a significantly higher specific memory B cell response in the older cohort, similar to responses obtained in the young cohort. CONCLUSION: The improved immune response to PhtD vaccine containing the AS02V adjuvant system in comparison to alum suggests that the reduced immune response to vaccines in older adults can be partially restored to the response level observed in young adults. ClinicalTrials.gov identifiers: NCT00307528/NCT01767402.


Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Formación de Anticuerpos , Antígenos Bacterianos/inmunología , Proteínas Bacterianas/inmunología , Inmunidad Celular , Vacunas Neumococicas/inmunología , Streptococcus pneumoniae/inmunología , Adyuvantes Inmunológicos/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Linfocitos B/inmunología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana Edad , Placebos/administración & dosificación , Vacunas Neumococicas/administración & dosificación , Vacunas Neumococicas/efectos adversos , Método Simple Ciego , Linfocitos T/inmunología , Vacunación/métodos , Adulto Joven
13.
Expert Rev Vaccines ; 13(10): 1159-62, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25089373

RESUMEN

First generation whole-cell (wP) and second generation acellular (aP) pertussis vaccines have been highly effective in preventing childhood deaths due to pertussis, yet both vaccines have drawbacks that have limited their long-term usefulness. These include issues of reactogenicity and potency in the case of wP, and limited durability of protection and the potential for selection of escape mutants in the case of aP. Neither vaccine prevents disease in neonatal infants who continue to die from pertussis. A third generation of pertussis vaccines that provides broad, durable protection is needed. In the meantime, countries using wP should continue to do so, while countries using aP need to consider policies and schedules that reduce pertussis transmission to unvaccinated infants. In this respect, maternal vaccination appears to be a promising solution.


Asunto(s)
Vacuna contra la Tos Ferina/uso terapéutico , Tos Ferina/inmunología , Tos Ferina/prevención & control , Humanos , Recién Nacido , Vacuna contra la Tos Ferina/inmunología , Vacunas Acelulares/inmunología
14.
Clin Vaccine Immunol ; 21(5): 651-60, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24599529

RESUMEN

Six vaccine formulations containing AS02V or alum (aluminum phosphate [AlPO4]) adjuvant with pneumococcal proteins, pneumococcal histidine triad D (PhtD), and/or detoxified pneumolysin (dPly), either as a polysaccharide carrier in an 8-valent pneumococcal conjugate vaccine (8PCV) or as free (unconjugated) proteins, were evaluated in adults -65 to 85 years of age. In this phase I observer-blind study, 167 healthy subjects were randomized to receive two doses (days 0 and 60) of 10 or 30 µg PhtD-dPly plus AS02V or alum, 8PCV plus AS02V or alum, or one dose (day 0) of 23-valent polysaccharide pneumococcal vaccine (23PPV) as a control (placebo on day 60). The safety, reactogenicity, and antibody-specific responses to these vaccines were evaluated. No vaccine-related serious adverse events were reported. The incidences of solicited local and specific general (fatigue and myalgia) symptoms tended to be higher in the AS02V groups than in other groups. Anti-PhtD and anti-Ply antibody responses were observed in all groups except the control group. One month post-dose 2, the anti-PhtD and anti-Ply antibody geometric mean concentrations tended to be higher with AS02V than with alum, higher with a dose of 30 µg than with 10 µg for PhtD-dPly and higher with 30-µg PhtD-dPly formulations than with conjugated PhtD and dPly (8PCV) formulations. Functional antibody responses, measured by an opsonophagocytic activity assay, tended to be higher with 8PCV than with 23PPV. In conclusion, vaccine formulations containing free or conjugated PhtD and dPly had acceptable reactogenicity and safety profiles in elderly adults. Immune responses were enhanced with an AS02V-adjuvanted formulation containing free 30-µg PhtD-dPly compared to those with alum adjuvant and conjugated proteins. (This study has been registered at ClinicalTrials.gov under registration no. NCT00756067.).


Asunto(s)
Adyuvantes Inmunológicos/efectos adversos , Compuestos de Alumbre/efectos adversos , Antígenos Bacterianos/inmunología , Vacunas Neumococicas/efectos adversos , Vacunas Neumococicas/inmunología , Saponinas/efectos adversos , Estreptolisinas/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Anciano , Anciano de 80 o más Años , Compuestos de Alumbre/administración & dosificación , Anticuerpos Antibacterianos/sangre , Proteínas Bacterianas/inmunología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/patología , Femenino , Humanos , Masculino , Proteínas Opsoninas/sangre , Fagocitosis , Placebos/administración & dosificación , Vacunas Neumococicas/administración & dosificación , Saponinas/administración & dosificación , Método Simple Ciego , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/efectos adversos , Vacunas de Subunidad/inmunología
15.
Vaccine ; 32(11): 1280-6, 2014 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-24486354

RESUMEN

Human volunteers were vaccinated with experimental Neisseria meningitidis serogroup B vaccines based on strain H44/76 detoxified L3 lipooligosaccharide (LOS)-derived outer membrane vesicles (OMV) or the licensed Cuban vaccine, VA-MENGOC-BC. Some volunteers were able to elicit cross-bactericidal antibodies against heterologous L2-LOS strain (760676). An immuno-proteomic approach was used to identify potential targets of these cross-bactericidal antibodies using an L2-LOS derived OMV preparation. A total of nine immuno-reactive spots were detected in this proteome: individuals vaccinated with the detoxified OMVs showed an increase in post-vaccination serum reactivity with Spots 2-8, but not with Spots 1 and 9. Vaccination with VA-MENGOC-BC induced sera that showed increased reactivity with all of the protein spots. Vaccinees showed increases in serum bactericidal activity (SBA) against the heterologous L2-LOS expressing strain 760676, which correlated, in general, with immunoblot reactivity. The identities of proteins within the immuno-reactive spots were determined. These included not only well-studied antigens such as Rmp, Opa, PorB and FbpA (NMB0634), but also identified novel antigens such as exopolyphosphatase (NMB1467) and γ-glutamyltranspeptidase (NMB1057) enzymes and a putative cell binding factor (NMB0345) protein. Investigating the biological properties of such novel antigens may provide candidates for the development of second generation meningococcal vaccines.


Asunto(s)
Proteínas de la Membrana Bacteriana Externa/inmunología , Reacciones Cruzadas/inmunología , Vacunas Meningococicas/inmunología , Proteoma/inmunología , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/inmunología , Ensayos Clínicos Fase I como Asunto , Humanos , Neisseria meningitidis Serogrupo B , Ensayos Clínicos Controlados Aleatorios como Asunto , Determinación de Anticuerpos Séricos Bactericidas
16.
PLoS Pathog ; 9(10): e1003733, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24204275

RESUMEN

The outer membrane of Gram-negative bacteria functions as a permeability barrier that protects these bacteria against harmful compounds in the environment. Most nutrients pass the outer membrane by passive diffusion via pore-forming proteins known as porins. However, diffusion can only satisfy the growth requirements if the extracellular concentration of the nutrients is high. In the vertebrate host, the sequestration of essential nutrient metals is an important defense mechanism that limits the growth of invading pathogens, a process known as "nutritional immunity." The acquisition of scarce nutrients from the environment is mediated by receptors in the outer membrane in an energy-requiring process. Most characterized receptors are involved in the acquisition of iron. In this study, we characterized a hitherto unknown receptor from Neisseria meningitidis, a causative agent of sepsis and meningitis. Expression of this receptor, designated CbpA, is induced when the bacteria are grown under zinc limitation. We demonstrate that CbpA functions as a receptor for calprotectin, a protein that is massively produced by neutrophils and other cells and that has been shown to limit bacterial growth by chelating Zn²âº and Mn²âº ions. Expression of CbpA enables N. meningitidis to survive and propagate in the presence of calprotectin and to use calprotectin as a zinc source. Besides CbpA, also the TonB protein, which couples energy of the proton gradient across the inner membrane to receptor-mediated transport across the outer membrane, is required for the process. CbpA was found to be expressed in all N. meningitidis strains examined, consistent with a vital role for the protein when the bacteria reside in the host. Together, our results demonstrate that N. meningitidis is able to subvert an important defense mechanism of the human host and to utilize calprotectin to promote its growth.


Asunto(s)
Proteínas de la Membrana Bacteriana Externa/inmunología , Proteínas Bacterianas/inmunología , Evasión Inmune , Neisseria meningitidis/inmunología , Zinc/inmunología , Proteínas de la Membrana Bacteriana Externa/genética , Proteínas de la Membrana Bacteriana Externa/metabolismo , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Humanos , Transporte Iónico/genética , Transporte Iónico/inmunología , Hierro/inmunología , Hierro/metabolismo , Complejo de Antígeno L1 de Leucocito/inmunología , Complejo de Antígeno L1 de Leucocito/metabolismo , Manganeso/inmunología , Manganeso/metabolismo , Neisseria meningitidis/genética , Neisseria meningitidis/metabolismo , Neutrófilos/inmunología , Neutrófilos/metabolismo , Zinc/metabolismo
17.
Expert Rev Vaccines ; 12(12): 1379-94, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24195479

RESUMEN

Pneumococcal conjugate vaccines (PCVs) differ in polysaccharide (PS) dose, carrier protein and conjugation method. PCV development proceeded initially upon principles successfully proven in Haemophilus influenzae type b (Hib) conjugate vaccine development. However, the need to successfully incorporate multiple serotypes while minimizing the total PS dose and total carrier protein load saw some early vaccine candidates fail. Dose-range studies of individual serotypes indicated that much lower PS doses were needed compared with Hib conjugate vaccines, although subsequent studies confirmed that lower Hib PS doses were possible. Furthermore, the immune response to individual serotype doses was carrier protein dependent. A 'one-size fits most' approach has characterized PS dose selection, but peculiarities of individual serotypes are increasingly apparent, raising the question whether re-formulation of PCVs to maximize individual serotype performance is needed.


Asunto(s)
Relación Dosis-Respuesta Inmunológica , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas/administración & dosificación , Vacunas Neumococicas/inmunología , Humanos , Infecciones Neumocócicas/inmunología , Vacunas Neumococicas/aislamiento & purificación , Vacunas Conjugadas/administración & dosificación , Vacunas Conjugadas/inmunología , Vacunas Conjugadas/aislamiento & purificación
18.
PLoS One ; 8(9): e72003, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24039731

RESUMEN

NhhA (Neisseria hia homologue) is an outer membrane protein from Neisseria meningitidis, the causative agent of meningococcal disease. The protein is surface exposed and its expression in a wide range of meningococcal strains suggests it is a promising vaccine candidate. In addition, immunization of mice with outer membrane vesicles of strains that overexpress NhhA in conjunction with one of TbpA, Omp85 or NspA results in synergistic bactericidal responses. We previously showed that the NhhA sequence is highly conserved between strains, with the majority of the differences localized to four distinct variable regions located in the amino-terminal region of the mature protein. In this study, N. meningitidis strains were constructed that over-express wild-type NhhA. Strains expressing truncated versions of NhhA, with deletions from the amino-terminal region that removed the most variable regions, were also made. These expression strains were also modified so that immunodominant, phase- and antigenically-variable outer membrane proteins were not expressed, truncated lipooligosaccharide (LOS) expression was genetically fixed (no phase variability), and capsular polysaccharide expression abolished. Outer membrane vesicles derived from these strains were used to immunize mice. As previously observed, a synergistic effect involving another antigen, TbpA, was required to demonstrate bactericidal activity. The highest bactericidal response against a heterologous strain was obtained with a truncated variant of NhhA. These results indicate that removal of (a) variable region(s) does not reduce bactericidal responses against NhhA, and that bactericidal targets exist in regions other than the variable N-teminus. This provides the basis for future examination of responses against truncated NhhA in protecting against heterologous NhhA strains, and further evaluation of truncated NhhA as a candidate for inclusion in a vaccine against all serogroups of N. meningitidis.


Asunto(s)
Proteínas de la Membrana Bacteriana Externa/inmunología , Meningitis Meningocócica/prevención & control , Vacunas Meningococicas/inmunología , Neisseria meningitidis/inmunología , Fragmentos de Péptidos/inmunología , Animales , Animales no Consanguíneos , Anticuerpos Antibacterianos/sangre , Femenino , Humanos , Meningitis Meningocócica/inmunología , Ratones , Vacunación , Potencia de la Vacuna
19.
Emerg Infect Dis ; 19(4): 566-73, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23628376

RESUMEN

Pathogenic Neisseria meningitidis isolates contain a polysaccharide capsule that is the main virulence determinant for this bacterium. Thirteen capsular polysaccharides have been described, and nuclear magnetic resonance spectroscopy has enabled determination of the structure of capsular polysaccharides responsible for serogroup specificity. Molecular mechanisms involved in N. meningitidis capsule biosynthesis have also been identified, and genes involved in this process and in cell surface translocation are clustered at a single chromosomal locus termed cps. The use of multiple names for some of the genes involved in capsule synthesis, combined with the need for rapid diagnosis of serogroups commonly associated with invasive meningococcal disease, prompted a requirement for a consistent approach to the nomenclature of capsule genes. In this report, a comprehensive description of all N. meningitidis serogroups is provided, along with a proposed nomenclature, which was presented at the 2012 XVIIIth International Pathogenic Neisseria Conference.


Asunto(s)
Cápsulas Bacterianas/genética , Cromosomas Bacterianos , Genes Bacterianos , Neisseria meningitidis/genética , Polisacáridos Bacterianos/genética , Cápsulas Bacterianas/metabolismo , Sitios Genéticos , Humanos , Espectroscopía de Resonancia Magnética , Infecciones Meningocócicas/microbiología , Familia de Multigenes , Neisseria meningitidis/clasificación , Neisseria meningitidis/aislamiento & purificación , Neisseria meningitidis/patogenicidad , Reacción en Cadena de la Polimerasa , Polisacáridos Bacterianos/biosíntesis , Polisacáridos Bacterianos/aislamiento & purificación , Serotipificación , Terminología como Asunto , Virulencia
20.
Infect Immun ; 81(6): 1915-27, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23509142

RESUMEN

Neisseria meningitidis serogroup B (MenB) is a major cause of bacterial sepsis and meningitis, with the highest disease burden in young children. Available vaccines are based on outer membrane vesicles (OMVs) obtained from wild-type strains. However, particularly in toddlers and infants, they confer protection mostly against strains expressing the homologous protein PorA, a major and variable outer membrane protein. In the quest for alternative vaccine antigens able to provide broad MenB strain coverage in younger populations, but potentially also across all age groups, ZnuD, a protein expressed under zinc-limiting conditions, may be considered a promising candidate. Here, we have investigated the potential value of ZnuD and show that it is a conserved antigen expressed by all MenB strains tested except for some strains of clonal complex ST-8. In mice and guinea pigs immunized with ZnuD-expressing OMVs, antibodies were elicited that were able to trigger complement-mediated killing of all the MenB strains and serogroup A, C, and Y strains tested when grown under conditions of zinc limitation. ZnuD is also expressed during infection, since anti-ZnuD antibodies were detected in sera from patients. In conclusion, we confirm the potential of ZnuD-bearing OMVs as a component of an effective MenB vaccine.


Asunto(s)
Proteínas Bacterianas/inmunología , Proteínas Bacterianas/metabolismo , Proteínas de Transporte de Catión/inmunología , Proteínas de Transporte de Catión/metabolismo , Infecciones Meningocócicas/prevención & control , Vacunas Meningococicas/inmunología , Neisseria meningitidis/metabolismo , Adolescente , Animales , Anticuerpos Antibacterianos/sangre , Antígenos Bacterianos/química , Antígenos Bacterianos/genética , Antígenos Bacterianos/inmunología , Antígenos Bacterianos/metabolismo , Proteínas Bacterianas/química , Proteínas Bacterianas/genética , Proteínas de Transporte de Catión/química , Proteínas de Transporte de Catión/genética , Niño , Preescolar , Femenino , Regulación Bacteriana de la Expresión Génica/fisiología , Cobayas , Humanos , Lactante , Ratones , Modelos Moleculares , Neisseria meningitidis/genética , Neisseria meningitidis/inmunología , Filogenia , Conformación Proteica , Determinación de Anticuerpos Séricos Bactericidas , Adulto Joven , Zinc/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA